Novo Nordisk A/S $NVO Shares Sold by Sunbelt Securities Inc.

Sunbelt Securities Inc. trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 73.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,741 shares of the company’s stock after selling 15,575 shares during the quarter. Sunbelt Securities Inc.’s holdings in Novo Nordisk A/S were worth $211,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Quotient Wealth Partners LLC increased its holdings in Novo Nordisk A/S by 2.0% in the fourth quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock valued at $463,000 after buying an additional 177 shares in the last quarter. Certuity LLC boosted its stake in shares of Novo Nordisk A/S by 3.6% during the 4th quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after acquiring an additional 177 shares in the last quarter. Oakworth Capital Inc. boosted its stake in shares of Novo Nordisk A/S by 41.6% during the 4th quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock worth $31,000 after acquiring an additional 182 shares in the last quarter. True North Advisors LLC grew its position in shares of Novo Nordisk A/S by 3.9% during the 4th quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock valued at $270,000 after acquiring an additional 199 shares during the period. Finally, Asio Capital LLC grew its position in shares of Novo Nordisk A/S by 3.9% during the 4th quarter. Asio Capital LLC now owns 5,386 shares of the company’s stock valued at $274,000 after acquiring an additional 200 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 8.5%

NVO opened at $47.20 on Friday. The company has a market cap of $210.74 billion, a PE ratio of 11.08, a price-to-earnings-growth ratio of 4.30 and a beta of 0.77. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The company has a 50-day moving average price of $46.92 and a 200 day moving average price of $45.50. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The company had revenue of $10.85 billion for the quarter. Sell-side analysts expect that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on NVO shares. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Zacks Research downgraded Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Finally, HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Five research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $65.56.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s existing obesity business remains a key support. The company recently received European approval for a once-daily Wegovy pill and partnered with Crux to expand access to Wegovy through U.S. employer health plans, potentially broadening distribution and affordability. Novo Nordisk Teams Up With Crux To Expand Wegovy Access
• Neutral Sentiment: Some investor commentary indicates that Novo Nordisk’s current revenue drivers, particularly its GLP-1 medicines, remain intact despite the pipeline setback. However, the failed trial increases reliance on those products for future growth. NVO Stock Slumps After Late-Stage Trial Fails Primary Goal
• Negative Sentiment: In the Phase 3 ZEUS trial, ziltivekimab failed to significantly reduce major adverse cardiovascular events versus placebo in patients with cardiovascular disease, chronic kidney disease and inflammation. The result eliminates or reduces the near-term commercial potential of a drug intended to expand Novo Nordisk’s cardiovascular portfolio. Novo Nordisk’s Inflammation Drug Fails to Reduce Cardiovascular Risk in Trial
• Negative Sentiment: The setback is weighing on investor confidence in Novo Nordisk’s pipeline and has pushed the stock lower as markets reassess future growth and valuation. Novo Nordisk Shares Dive After Heart Medicine Fails Trial
• Negative Sentiment: Erste Group Bank also trimmed its fiscal 2026 earnings estimate to $3.20 per share from $3.22, below the $3.39 consensus estimate, adding to the cautious outlook. Novo Nordisk Analyst Estimate Update

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.